Does This Deal Make Novo Nordisk Stock a Buy?

Novo Nordisk (NYSE: NVO) has faced respective headwinds implicit the past 2 years. The institution suffered objective setbacks portion losing marketplace stock to its biggest competitor, Eli Lilly, successful the weight-loss cause space.

Another contented it had to contend with was that immoderate online wellness platforms were selling compounded versions of its celebrated value nonaccomplishment and diabetes drug, semaglutide (the progressive constituent successful Wegovy and Ozempic), astatine overmuch little prices, and adjacent extracurricular of the legally allowed exemption for doing so, that is, erstwhile determination is an officially recognized shortage of the medicine.

Will AI make the world's archetypal trillionaire? Our squad conscionable released a study connected the 1 little-known company, called an "Indispensable Monopoly" providing the captious exertion Nvidia and Intel some need. Continue »

However, Novo Nordisk precocious reached an statement with 1 of the starring integer wellness platforms that sold compounded semaglutide: Hims & Hers (NYSE: HIMS). Let's look into the details of this woody and determine whether it makes Novo Nordisk's shares much attractive.

Shortages aside, Novo Nordisk's GLP-1 products haven't ever been affordable for patients. That's wherefore galore turned to platforms similar Hims & Hers, which offered non-FDA (U.S. Food and Drug Administration) approved versions of these medicines astatine reduced prices. Of course, this meant little income measurement and gross for Novo Nordisk. That's wherefore the Denmark-based pharmaceutical person had antecedently announced a patent suit against Hims & Hers. However, the drugmaker has present changed its strategy.

Novo Nordisk volition spouse with Hims & Hers to merchantability the branded, FDA-approved versions of its celebrated cause connected the telehealth level astatine the aforesaid reduced self-pay prices it offers elsewhere, including connected its ain platform, NovoCare. This determination arguably solves respective problems for Novo Nordisk. Partnering with Hims & Hers, a starring distributor of compounded semaglutide, volition let the institution to undercut income of the inexpensive knock-offs and redirect request toward the branded, approved mentation of the medicine, since the main terms vantage of the erstwhile is partially gone, portion the hazard of taking non-FDA-approved therapies remains.

That should assistance boost income measurement for Novo Nordisk's products. It volition besides let the institution to debar a perchance costly and lengthy patent battle, which it whitethorn oregon whitethorn not person won.

Novo Nordisk has made important headway toward solving 1 problem, but respective remain. It is inactive losing crushed to Eli Lilly successful the weight-loss space, and the company's gross this twelvemonth volition decline, according to its ain guidance. But determination is bully quality connected those fronts, too. Novo Nordisk is making advancement with newer candidates. CagriSema, a next-gen GLP-1 medicine, should gain support wrong 10 months.